DIVISION OF PUBLIC and BEHAVIORAL HEALTH

Policy

Control #	Rev.	Туре	Title	Effective Date	Page
MME XXX			Cannabinoid and Terpenoid Testing	x-xx-15	1 of 3

1.0 POLICY

The Nevada Division of Public and Behavioral Health (DPBH or the Division) shall establish a list of cannabinoids and terpenoids for which medical marijuana will be tested. This policy is in accordance with NRS 453A.368 which states:

NRS 453A.368 Testing laboratories. [Effective April 1, 2014.]

1. The Division shall establish standards for and certify one or more private and independent testing laboratories to test marijuana, edible marijuana products and marijuana-infused products that are to be sold in this State.

2. Such an independent testing laboratory must be able to determine accurately, with respect to marijuana, edible marijuana products and marijuana-infused products that are sold or will be sold at medical marijuana dispensaries in this State:

(a) The concentration therein of THC and cannabidiol.

(b) The presence and identification of molds and fungus.

(c) The composition of the tested material

(d) The presence of chemicals in the tested material, including, without limitation, pesticides, herbicides or growth regulators.

This policy is also in accordance with NAC 453A.658(2) which states:

NAC 453A.658 Sample testing; disposal of samples; standards; laboratory test results; grounds for disciplinary action. (<u>NRS 453A.370</u>)

2. An independent testing laboratory that receives a sample pursuant to this section shall test the sample for cannabinoids, terpenoids, microbial contaminants, mycotoxins, heavy metals and pesticide chemical residue, residual solvents levels and for purposes of conducting an active ingredient analysis, as specified in the policy manual for independent testing laboratories created by the Division.

On May 6, 2015, the Independent Laboratory Advisory Council (ILAC) recommended the Division adopt the following cannabinoids for purposes of determining the cannabinoid profile of a medical marijuana sample: THC, THCA, CBD and CBN. The Division has adopted this recommendation for cannabinoid testing as recommended. Additionally, the ILAC recommended the Division adopt ten (10) terpenoids for purposes of determining the terpenoid profile of a medical marijuana sample: Alpha-Bisabolol, Alpha-Humulene, Alpha-Pinene, Alpha-Terpinolene, Beta-Caryophyllene, Beta-Myrcene, Beta-Pinene, Caryophyllene Oxide, Limonene and Linalool. In addition to these ten terpenoids, independent testing laboratories will test for the following five (5) terpenoids: Alpha-Terpinene, Beta-Eudesmol, Camphene, Cis-Ocimene and Delta-Carene.




DIVISION OF PUBLIC and BEHAVIORAL HEALTH

Policy

Control #	Rev.	Туре	Title	Effective Date	Page
MME XXX			Cannabinoid and Terpenoid Testing	x-xx-15	2 of 3

Independent Testing Laboratories shall test for and quantify the presence of the following cannabinoids and terpenoids:

Cannabinoids
THC
THCA
CBD
CBN



2.0 PURPOSE

The purpose of this policy is to provide a list of cannabinoids and terpenoids to be identified and quantified through testing by Independent Testing Laboratories in order to satisfy labeling requirements and provide results to patients.

3.0 SCOPE

This policy applies to all Nevada Medical Marijuana Establishments (MME).

4.0 **PROCEDURE**

4.1 Each Independent Testing Laboratory will collect a random sample from a cultivator or production facility for testing, as specified in NAC 453A.658, and will test it for the cannabinoids and terpenoids specified in paragraph 1.0 of this policy.



DIVISION OF PUBLIC and BEHAVIORAL HEALTH Policy

Control #	Rev.	Туре	Title	Effective Date	Page
MME XXX			Cannabinoid and Terpenoid Testing	x-xx-15	3 of 3

4.2 After identifying and quantifying cannabinoids and terpenoids, Independent Testing Laboratories shall provide this information to the cultivator or production facility from which the sample was drawn.

4.3 MMEs shall label products to identify the cannabinoid and terpenoid profile, as applicable, in accordance with NAC 453A.508, NAC 453A.510 and NAC 453A.512.

5.0 RELATED DOCUMENTS

Upton, Roy, Lyle Cracker, Mahmoud ElSohly, Aviva Romm, Ethan Russo, and Michelle Sexton. "Cannabis Inflorescence." *American Herbal Pharmacopoeia (2014):* Print.

